Welcome to our dedicated page for Savara SEC filings (Ticker: SVRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Savara Inc. filings document a clinical-stage biopharmaceutical issuer focused on rare respiratory diseases and its development of molgramostim inhalation solution for autoimmune pulmonary alveolar proteinosis. The record includes Nasdaq-listed common stock disclosures, Regulation FD corporate presentations, clinical and regulatory updates, operating and financial results, and material-event reports tied to business operations.
Recent filings also cover definitive proxy materials, board and compensation matters, shareholder voting matters, lease obligations, and debt arrangements under a loan and security agreement. These disclosures describe Savara's capital structure, financing covenants, material agreements, governance practices and corporate reporting obligations.
Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases, built around its sole product candidate, MOLBREEVI (molgramostim inhalation solution) for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). The drug is an inhaled form of GM-CSF delivered via PARI’s proprietary eFlow nebulizer.
The company’s Phase 3 IMPALA-2 trial in autoimmune PAP met its primary endpoint, showing statistically significant improvement in gas exchange (DLCO) and supporting clinical benefit on respiratory quality of life and exercise capacity, with generally well-tolerated safety. A pediatric trial (IMPACT) and an expanded access program are ongoing.
Savara resubmitted a biologics license application for MOLBREEVI in autoimmune PAP in December 2025, and in February 2026 the FDA filed the application and granted Priority Review. The candidate holds multiple regulatory incentives, including Orphan Drug, Fast Track, Breakthrough Therapy, Innovation Passport, and Promising Innovative Medicine designations, as well as European patents protecting the liquid formulation and the MOLBREEVI–eFlow drug-device combination into the 2040s.
The company outsources manufacturing to GEMA, Fujifilm, and Patheon and has exclusive device supply from PARI. Under a purchase and sale agreement with funds managed by RTW Investments, Savara may receive $75 million upon FDA approval of MOLBREEVI by March 31, 2027, in exchange for tiered royalties on U.S. net sales up to an aggregate $187.5 million, with a buy-back option tied to certain change-of-control events.
Venrock-affiliated investment entities report beneficial ownership of 20,881,288 Savara Inc. shares, representing 9.99% of the common stock as of December 31, 2025. This stake comes from common shares and pre-funded warrants held across several Venrock Healthcare Capital Partners funds.
The pre-funded warrants include a 9.99% Beneficial Ownership Blocker, which prevents additional exercises that would push the group’s ownership above that level. The reporting group certifies that the securities are not held for the purpose of changing or influencing control of Savara.
Savara Inc director Joseph S. McCracken exercised stock options on February 16, 2026 to acquire 1,807 shares of common stock at $1.76 per share. These options, granted at an exercise price of $1.76, had vested in twelve equal quarterly installments beginning on March 15, 2017. After this option exercise, McCracken directly holds 302,644 shares of Savara common stock.
Savara Inc. received an updated ownership report from TCG Crossover entities and Chen Yu. They report beneficial ownership of 12,362,205 shares of Savara common stock, representing 6.1% of the class, based on 203,467,845 shares outstanding as of November 12, 2025.
The shares are held of record by TCG Crossover Fund I, L.P., with TCG Crossover GP I, LLC as its general partner and Chen Yu as sole managing member, giving them shared voting and dispositive power. The filers state the holdings are not for the purpose of changing or influencing control of Savara.
Savara Inc. (SVRA) received an amended Schedule 13G filing from a group of Frazier Life Sciences investment entities reporting beneficial ownership of less than 5% of its common stock.
Frazier Life Sciences Public Fund, L.P. directly holds 8,343,048 shares, representing 4.1% of the class based on 203,467,845 shares outstanding as of November 12, 2025. Frazier Life Sciences X, L.P. directly holds 279,365 shares (0.1%), and Frazier Life Sciences XI, L.P. directly holds 1,239,888 shares (0.6%).
The reporting persons certify the securities were not acquired or held to change or influence control of Savara and disclaim being part of a control group, other than for limited nomination activities cited in the certification language.
Savara Inc. (SVRA) received an amended Schedule 13G from Nantahala Capital Management and its principals, Wilmot B. Harkey and Daniel Mack, reporting their beneficial ownership in the company’s common stock. As of December 31, 2025, they may be deemed to beneficially own 7,344,783 shares, representing 3.61% of Savara’s outstanding common stock.
The filing shows they have no sole voting or dispositive power, but share voting and dispositive power over all reported shares through funds and accounts managed by Nantahala. The securities are stated to be held in the ordinary course of business and not for the purpose of changing or influencing control of Savara.
Savara Inc. received an updated Schedule 13G/A (Amendment No. 10) from a group of Farallon-managed investment funds reporting their beneficial ownership in the company’s common stock. The Farallon funds collectively hold 15,000,000 Common Stock Purchase Warrants, each currently exercisable to buy one Savara share.
Because the warrants contain a 9.99% Beneficial Ownership Limitation, Farallon reports beneficial ownership of 6.9% of Savara’s common stock, based on assuming all 15,000,000 warrants are exercisable within 60 days. The amendment also updates the listed individual reporting persons, adding Avner A. Husen and removing Richard B. Fried, Rajiv A. Patel, and William Seybold as of year-end 2025.
Savara Inc. entered into a First Amendment to its Loan and Security Agreement with Hercules Capital and other lenders. As amended, the agreement allows the company to borrow up to an aggregate of $105 million in term loans. The amendment resets the timing and conditions for Savara to draw up to $75 million of additional term loans, which become available only if the FDA approves its MOLBREEVI product candidate for treating aPAP. It also pushes back the initial dates for certain cash and revenue financial covenants to April 1, 2027 and September 30, 2027 if Savara’s market capitalization falls below specified thresholds, and grants lenders a first‑priority security interest in the company’s intellectual property, which can revert to a negative pledge if a related purchase agreement is terminated and unrestricted cash remains at or above $50 million.
BlackRock, Inc. has disclosed a significant ownership stake in Savara Inc. common stock on a Schedule 13G. BlackRock reports beneficial ownership of 10,957,322 shares of Savara common stock, representing 5.4% of the outstanding class as of the event date 12/31/2025. BlackRock has sole voting power over 10,820,963 shares and sole dispositive power over 10,957,322 shares, with no shared voting or dispositive power.
The filing states that these securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Savara. Various underlying clients and investors have the right to receive dividends or sale proceeds, but no single person has more than five percent of the total outstanding common shares.
Savara Inc. has furnished an updated corporate presentation for investors. The presentation is available on the company’s Investor Relations website and has also been provided as Exhibit 99.1 to a current report. Savara states it has no duty to update or revise the presentation, although it may choose to do so through its website, future SEC reports, press releases, or other public disclosures. The information in this investor presentation is expressly treated as furnished rather than filed under securities laws and is not automatically incorporated into other SEC filings unless specifically referenced.